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ABSTRACT
Objective To test if patients recovering from COVID-19 
are at increased risk of mental morbidities and to what 
extent such risk is exacerbated by illness severity.
Design Population- based cross- sectional study.
Setting Iceland.
Participants A total of 22 861 individuals were recruited 
through invitations to existing nationwide cohorts and a social 
media campaign from 24 April to 22 July 2020, of which 373 
were patients recovering from COVID-19.
Main outcome measures Symptoms of depression (Patient 
Health Questionnaire), anxiety (General Anxiety Disorder 
Scale) and posttraumatic stress disorder (PTSD; modified 
Primary Care PTSD Screen for DSM-5) above screening 
thresholds. Adjusting for multiple covariates and comorbidities, 
multivariable Poisson regression was used to assess the 
association between COVID-19 severity and mental morbidities.
Results Compared with individuals without a diagnosis of 
COVID-19, patients recovering from COVID-19 had increased 
risk of depression (22.1% vs 16.2%; adjusted relative risk 
(aRR) 1.48, 95% CI 1.20 to 1.82) and PTSD (19.5% vs 15.6%; 
aRR 1.38, 95% CI 1.09 to 1.75) but not anxiety (13.1% vs 
11.3%; aRR 1.24, 95% CI 0.93 to 1.64). Elevated relative risks 
were limited to patients recovering from COVID-19 that were 
40 years or older and were particularly high among individuals 
with university education. Among patients recovering from 
COVID-19, symptoms of depression were particularly common 
among those in the highest, compared with the lowest tertile 
of influenza- like symptom burden (47.1% vs 5.8%; aRR 6.42, 
95% CI 2.77 to 14.87), among patients confined to bed for 
7 days or longer compared with those never confined to bed 
(33.3% vs 10.9%; aRR 3.67, 95% CI 1.97 to 6.86) and among 
patients hospitalised for COVID-19 compared with those never 
admitted to hospital (48.1% vs 19.9%; aRR 2.72, 95% CI 1.67 
to 4.44).
Conclusions Severe disease course is associated with 
increased risk of depression and PTSD among patients 
recovering from COVID-19.
INTRODUCTION
With almost 180 million reported cases and 
3.9 million deaths globally,1 the COVID-19 
pandemic remains a major public health chal-
lenge worldwide. Beyond the extensive socioeco-
nomic impact and suffering of patients during 
Strengths and limitations of this study
 ► To our knowledge, this is the first study addressing 
mental morbidities among recovering COVID-19 
patients in a general population setting, including 
outpatients.
 ► This study includes more than 20% of all patients 
diagnosed with COVID-19 by reverse transcription- 
PCR during the first wave of the epidemic in Iceland, 
where the diagnostic rate was among the highest 
worldwide, allowing us to perform sensitivity analy-
ses limited to individuals who all had been screened 
for SARS- CoV-2.
 ► The extensive and well- piloted questionnaire al-
lowed us to obtain validated symptom assessment 
of mental morbidities along with detailed informa-
tion on influenza- like symptom burden for all indi-
viduals during the influenza season in Iceland.
 ► The cross- sectional design is less informative on 
the directionality of the studied associations, and as 
the study is nested within a small, economically and 
socially secure society, the generalisability of the 
findings may be limited.
 ► It is possible that individuals with severe symptoms 
of depression and anxiety were more likely to re-
port high levels of influenza- like symptoms during 
the preceding 2 months when responding to the 
questionnaire, yielding an outcome- dependent 
misclassification.
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the illness, there are rising concerns about long- term somatic 
and psychological impact on recovering patients.2–6
Mental health consequences among patients in recent 
epidemics are well documented.7 8 With respect to COVID-
19, a meta- analysis of 31 studies suggested a 45%–47% 
pooled prevalence of mild to severe symptoms of depres-
sion and anxiety in patients with COVID-19, mostly 
inpatients.9 Moreover, extreme rates of posttraumatic 
stress have been reported among COVID-19 inpatients 
in China.10 11 Previous studies are often small, limited to 
inpatients and some lack a control group. Fewer studies 
have reported symptoms of mental morbidities after 
recovery from COVID-19, with existing data suggesting 
high levels of symptoms12 and elevated rates of diagnosed 
psychiatric disorders among COVID-19 inpatients during 
the first weeks and months after hospital discharge.13–15
Influenza- like symptoms, such as myalgia, cough and sore 
throat, have been associated with mental morbidities in the 
general population during the COVID-19 pandemic.16 17 
To what extent influenza- like symptoms are associated with 
psychological distress in patients recently recovered from 
COVID-19 remains unknown. There are several mechanisms 
through which COVID-19 may be associated with mental 
morbidity. First, uncertainty regarding the disease course may 
give rise to symptoms of anxiety and depression in infected 
patients.18 Second, serious infection may induce a cytokine 
storm,19 20 leading to exacerbation of the illness and develop-
ment of psychological symptoms such as depression.19 The 
reverse may also be true that psychological symptoms may 
cause more severe COVID-19 illness through excessive or 
dysregulated inflammation.21
The first wave of COVID-19 in Iceland started on 28 
February 2020. Through modest but systematic mitigation 
strategies,22 the incidence of COVID-19 had effectively been 
attenuated by the end of April 2020, with only sporadic cases 
occurring until the onset of the second wave of infections on 
22 July. During this period, more than 20% of the total popu-
lation was tested using reverse transcription- PCR (RT- PCR); 
a total of 1820 tested positive for SARS- CoV-2 (0.5% of the 
total population), of whom 113 were hospitalised (6%) and 
10 died (0.5%).23 Here, we explore mental health indicators 
in patients recovering from COVID-19 in the first wave of the 
pandemic and the potential role of disease severity on the 
risk of mental morbidities.
METHODS
Study population and design
The COVID-19 National Resilience Cohort was estab-
lished on 24 April 2020, with the overarching aim of 
understanding the long- term public health impact of 
the COVID-19 epidemic in Iceland.24 Eligible were all 
Icelandic and English- speaking individuals 18 years or 
older who had an Icelandic electronic ID (total popu-
lation ≥18 years on 1 January 2020 was 282 77025). 
Recruitment was mainly through social media and 
public media coverage, although participants in ongoing 
cohort studies (The SAGA (Stress- And- Gene- Analysis) 
cohort (N=31 795 women); iStopMM (N=80 730 men 
and women) and Health and well- being of Icelanders 
(N=6102 men and women)) received email or postal 
invitations to participate. In addition, all individuals in 
Iceland who tested positive by RT- PCR for SARS- CoV-2 
through May 2020 (N=1800) received a text message 
invitation on 3 June 2020. All participants signed an elec-
tronic informed consent and subsequently answered a 
web- based questionnaire. The study was approved by the 
National Bioethics Committee (number 20-073) and the 
Data Protection Authority.
We performed a cross- sectional analysis of participants 
responding to the baseline questionnaire from 24 April 
through 22 July 2020. A total of 22 680 individuals had 
participated at that time point. We excluded individuals 
who did not state whether or not they had undergone a 
diagnostic test (n=989) or been diagnosed with COVID-19 
(n=19) and those who did not answer all questions on 
influenza- like symptoms (n=762) or all items in any one 
of the three measures of depression, anxiety and posttrau-
matic stress (n=49) (see online supplemental figure 1). 
The final analytic sample consisted of 20 861 participants.
Measures
Sociodemographic and health-related factors
Sociodemographic information included the date of 
response to the baseline questionnaire, gender, age, 
education, average monthly income during the past 
year, relationship status and residency (capital vs other 
regions). We defined relationship status as either being 
in a relationship (married, cohabiting or in a relationship 
yet not cohabiting) or not (single, widowed or divorced). 
Highest level of education was defined as (1) compulsory, 
(2) upper secondary/vocational/other, (3) university 
examination (bachelor’s degree or diploma certificate) 
or (4) master’s or doctoral degree. Monthly income 
categories were defined as (1) low income, <1653 GBP 
(British pound sterling); (2) low–medium income, 1653–
2755 GBP; (3) medium income, 2756–3858 GBP; (4) 
medium–high income, 3859–5511 GBP; (5) high income, 
>5511 GBP (conversion rates according to The Central 
Bank of Iceland, 24 April 202026).
Health- related information included current smoking 
status (yes/no), binge drinking during the past 2 months 
(defined as ≥4 drinks for women and ≥5 drinks for men 
or other genders27), a previous diagnosis of a psychi-
atric disorder (made by physicians or psychologists; yes/
no) and previous diagnosis of somatic comorbidities 
including hypertension, diabetes, heart disease, lung 
disease, chronic kidney disease, cancer and immuno-
suppressive state or immunosuppressive therapy (none, 
one or two or more comorbid conditions). Additionally, 
participants reported their height (m) and weight (kg), 
which was used to estimate body mass index as kg/m2.
Diagnosis of COVID-19 and illness severity
We asked participants whether they had been tested 
for COVID-19 regardless of testing method. If they 
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responded yes, we asked whether they had been diag-
nosed with COVID-19, and if so, how long ago they had 
been diagnosed, how long they were confined to bed due 
to COVID-19, and whether they had been hospitalised.
As the first wave of COVID-19 coincided with the influ-
enza season in Iceland, we asked all participants how 
many days they had experienced nine specific influenza- 
like symptoms over the preceding 2 months. The symp-
toms, previously identified as relevant for COVID-19,28 29 
were fever, cough, sore throat, impaired sense of taste 
or smell, headache, myalgia (body aches), gastroin-
testinal symptoms (abdominal pain, nausea, vomiting, 
diarrhoea), shortness of breath, fatigue and weakness. 
Response options were ‘never’, ‘1–2 days’, ‘3–6 days’, ‘1–2 
weeks’ and ‘more than 2 weeks’, which were scored from 
‘0’ (never) to ‘4’ (≥2 weeks). We calculated influenza- like 
symptom burden by summing all symptom scores indi-
cated by each participant (range 0–36 points) and then 
divided scores into tertiles of the distribution within the 
COVID-19 cohort (lowest 0–11, mid 12–23, highest 24–36 
points).
Symptoms of mental illness
We used the 9- item Patient Health Questionnaire (PHQ-9) 
to measure symptoms of depression with the recom-
mended cut- off of ≥10 points serving as a screening indi-
cator for depression in an adult primary care sample.30 
We used the 7- item Generalised Anxiety Disorder scale 
(GAD-7) to assess symptoms of anxiety. A cut- off of ≥10 
was employed as an indicator of moderate to severe symp-
toms of a generalised anxiety disorder in an adult primary 
care sample.31 The 5- item Primary Care PTSD Screen for 
DSM-5 (PC- PTSD-5) was used to measure symptoms of 
posttraumatic stress,32 with a modified version tailored 
to COVID-19 (eg, ‘Had nightmares about COVID-19?’). We 
scored the responses as ‘0’ (never) or ‘1’ (seldom, some-
times, often, very often) with a total score ranging from 0 
to 5. We defined COVID-19- specific posttraumatic stress 
disorder (PTSD) as a PC- PTSD- DSM-5 score of ≥4, which 
has previously been reported as optimal.32
Statistical analysis
First, we contrasted the distribution of sociodemographic 
and health- related factors between individuals with and 
without a COVID-19 diagnosis. We then ran univariable 
and multivariable linear regression to detect potential 
differences in continuous symptoms of depression (PHQ-
9), anxiety (GAD-7) and PTSD (PC- PTSD-5) across groups 
with and without a confirmed COVID-19 diagnosis. We 
used robust (modified) Poisson regression, with the clas-
sical sandwich estimator,33 to determine the association 
between a confirmed diagnosis of COVID-19 and risk of 
depression, anxiety or PTSD surpassing cut- offs of poten-
tial clinical significance. The association is presented as 
unadjusted and adjusted relative risks (aRRs) with 95% 
CIs and as prevalence differences. All multivariable 
models included age (continuous), gender (male, female 
or other), educational level (classification described 
above), income (continuous), current smoking (yes/no), 
previous diagnosis of a psychiatric disorder (yes/no), 
number of previously diagnosed somatic diseases (0, 1 or 
≥2) and the time period of responding to the baseline 
questionnaire (24–30 April, 1–7 May, 8–23 May or 24 May 
to 22 July). We then performed these analyses stratified 
by all covariates and performed a likelihood ratio test for 
effect modification.
We performed several sensitivity analyses. As we were 
concerned for a potential overlap between physical symp-
toms of COVID-19 and some items on the mental health 
assessments (eg, fatigue), we performed a sensitivity 
analysis excluding patients diagnosed with COVID-19 
within 14 days of responding to the questionnaire. We 
further reran the analysis using individuals tested, but 
not positive for COVID-19 as a control group. There was 
a considerable difference between individuals with and 
without a COVID-19 diagnosis with respect to the date of 
responding to the questionnaire (table 1). Therefore, we 
repeated the multivariable Poisson regression stratified 
by questionnaire answer date, divided into two groups 
(24 April to 7 May and 8 May to 22 July). Finally, as our 
primary Poisson regression analysis included individuals 
with complete responses to PHQ-9 (n=18 822), GAD-7 
(n=19 163) and PC- PTSD-5 (n=17 562), we repeated these 
analyses, including the entire analytic sample (n=20 861), 
using multiple imputation by creating 10 imputed data 
sets with 10 iterations each.34
Limited to individuals diagnosed with COVID-19, we 
used multivariable Poisson regression to evaluate the 
association between indicators of COVID-19 severity and 
mental morbidities. Adjusting for the same covariates as 
listed above, we explored the association between time 
confined to bed due to COVID-19 (never vs 1–6 days 
or 7 days or more), influenza- like symptom burden (in 
tertiles) and whether or not patients had been hospi-
talised, and mental morbidities among recovering 
patients.
Next, we compared the proportion of individuals 
with and without a COVID-19 diagnosis (tested and not 
tested for SARS- CoV-2) who reported each of the nine 
influenza- like symptoms for 1 week or more. We used 
robust Poisson regression to calculate unadjusted and 
multivariable- aRRs of each symptom among individuals 
tested versus not tested for SARS- CoV-2 and then diag-
nosed versus not diagnosed with COVID-19. The multi-
variable models included the same covariates as listed 
above. Using linear regression, we then tested the asso-
ciation between influenza- like symptom burden and 
mental morbidities both among individuals with and 
without a diagnosis of COVID-19 (tested and not tested 
for SARS- CoV-2). We then tested whether influenza- like 
symptoms mediated the association between a confirmed 
COVID-19 diagnosis and mental morbidities by adding 
influenza- like symptoms to the multivariable models. All 
analyses were conducted in R (V.3.6.2).
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Patient and public involvement
No patients were involved in putting forward the research 
question or the outcome measures, nor were they involved 
in developing plans for design or implementation of the 
study. Dissemination of the results to study participants 
and the Icelandic population will be obtained through a 
media outreach (eg, press release and communication on 
our study website) on publication of this study.
RESULTS
Background characteristics
Of the 20 861 participants, 5419 individuals had been 
tested for SARS- CoV-2, of whom 373 reported having 
been diagnosed with COVID-19 (97.9% more than 
2 weeks before responding to the questionnaire; table 1). 
Compared with other participants, individuals previously 
diagnosed with COVID-19 were younger (mean age: 48.3 
vs 54.8 years), had a higher educational level and income 
and were more likely to binge drink alcohol. They were 
furthermore less likely to be current smokers and have 
Table 1 Characteristics of the study population, with and 












  Male 6133 (29.9) 121 (32.4) 0.15
  Female 14 306 (69.8) 250 (67.0)
  Other 36 (0.2) 2 (0.5)
  Missing 13 (0.1) 0 (0)
Age
  18–29 years 1191 (5.8) 51 (13.7) <0.001
  30–39 years 1949 (9.5) 39 (10.5)
  40–49 years 3644 (17.8) 99 (26.5)
  50–59 years 5309 (25.9) 99 (26.5)
  60–69 years 5359 (26.2) 74 (19.8)
  70 years or older 3036 (14.8) 11 (2.9)
Highest educational level
  Compulsory education 2865 (14.0) 30 (8.0) 0.008
  Upper secondary, 
vocational or other 
education
6303 (30.8) 117 (31.4)
  Bachelor’s degree or 
diploma certificate
6517 (31.8) 135 (36.2)
  Master’s or PhD degree 4685 (22.9) 91 (24.4)
  Missing 118 (0.6) 0 (0)
Average monthly income*
  Low income 3527 (17.2) 50 (13.4) <0.001
  Low- medium income 5642 (27.5) 88 (23.6)
  Medium income 4993 (24.4) 82 (22.0)
  Medium- high income 3527 (17.2) 91 (24.4)
  High income 1825 (8.9) 47 (12.6)
  Missing 974 (4.8) 15 (4.0)
Residence
  Capital area 13 986 (68.3) 270 (72.4) 0.18
  Elsewhere in Iceland 6352 (31.0) 102 (27.3)
  Abroad 140 (0.7) 1 (0.3)
  Missing 10 (0.0) 0 (0)
Marital status
  In a relationship 15 735 (76.8) 302 (81.0) 0.09
  Single 4671 (22.8) 71 (19.0)
  Missing 82 (0.4) 0 (0)
BMI category (kg/m²)
  <25, normal weight 5931 (28.9) 112 (30.0) 0.70
  25–30, overweight 7931 (38.7) 138 (37.0)
  >30, obese 6127 (29.9) 118 (31.6)
  Missing 499 (2.4) 5 (1.3)
Smoking status
  No 17 873 (87.2) 345 (92.5) 0.002
  Yes 2521 (12.3) 26 (7.0)













  No 18 255 (89.1) 312 (83.6) 0.02
  Yes 2233 (10.9) 61 (16.4)
Previous diagnosis of 
psychiatric disorder
  No 14 510 (70.8) 285 (76.4) 0.02
  Yes 5776 (28.2) 84 (22.5)
  Missing 202 (1.0) 4 (1.1)
Physical diseases
  No comorbidities 11 958 (58.4) 263 (70.5) <0.001
  One comorbidity 5964 (29.1) 86 (23.1)
  Two or more 
comorbidities
2453 (12.0) 21 (5.6)
  Missing 113 (0.6) 3 (0.8)
Questionnaire answer 
date
  24–30 April 7841 (38.3) 102 (27.3) <0.001
  1–7 May 5413 (26.4) 76 (20.4)
  8–23 May 4999 (24.4) 53 (14.2)
  24 May–22 July 2235 (10.9) 142 (38.1)
Time since diagnosis
  Less than 2 weeks – 8 (2.1) –
  2–4 weeks – 60 (16.1)
  More than 4 weeks – 305 (81.8)
*Income categories were defined as: low income, <1653 GBP; low- medium 
income, 1653–2755 GBP; medium income, 2756–3858 GBP; medium- 
high income, 3859–5511 GBP; high income, >5511 GBP (conversion rates 
according to Central Bank of Iceland, 24 April 2020).
Table 1 Continued
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previously been diagnosed with psychiatric disorders or 
somatic diseases. The analytic sample had similar educa-
tion35 and residence distribution as the general popula-
tion, while the median age was higher and women were 
over- represented.36
COVID-19 and mental morbidities
Individuals diagnosed with COVID-19 reported, 
compared with others, higher mean scores of depression 
(6.11 vs 5.07; p<0.001) and PTSD (1.90 vs 1.72; p<0.001), 
but not anxiety (4.52 vs 4.12; p=0.08; see online supple-
mental table 1). Similarly, multivariable- aRRs of depres-
sion (22.1% vs 16.2%; aRR 1.48, 95% CI 1.20 to 1.82) and 
PTSD (19.5% vs 15.6%; aRR 1.38, 95% CI 1.09 to 1.75) 
above symptom thresholds were increased among those 
recovering from COVID-19 compared with others, while 
not on anxiety (13.1% vs 11.3%; aRR 1.24, 95% CI 0.93 
to 1.64; table 2). Risk elevations in mental morbidity in 
individuals diagnosed with COVID-19 were limited to 
those 40 years or older and was highest among individ-
uals 60 years or older (see online supplemental table 
2). Individuals with higher educational level were more 
likely to suffer from symptoms of depression and anxiety 
after a diagnosis of COVID-19. When stratified by answer 
date, risk elevations for depression and anxiety in patients 
recovering from COVID-19 were lower for those who 
answered in the later response period (ie, 8 May to 22 
July), whereas it was higher for PTSD (see online supple-
mental table 2) and no statistically significant interactions 
were observed. Limiting the analysis to individuals who 
were diagnosed with COVID-19 more than 2 weeks before 
responding to the questionnaire and repeating the anal-
ysis using multiple imputation yielded virtually identical 
results (see online supplemental tables 3,4). Finally, 
limiting the analysis to individuals who were tested for 
COVID-19 generated a similar pattern yet slightly lower 
point estimate (see online supplemental table 5).
COVID-19 illness severity and mental morbidities
In table 3, we show the prevalence and aRRs of 
mental morbidities among individuals with a diag-
nosis of COVID-19 by number of days confined to bed, 
hospitalisation and severity of COVID-19 symptoms. We 
observed dose- dependent associations between these 
indices of COVID-19 severity and risk of mental morbid-
ities. Risk elevations by days confined to bed and hospi-
talisation due to COVID-19 were statistically significant 
for depression and anxiety, while influenza- like symptom 
burden was associated with all measures of mental 
morbidity.
Influenza-like symptoms and mental morbidities
In figure 1, we present the proportions of individuals with 
influenza- like symptoms lasting at least 1 week during the 
preceding 2 months among patients recovering from COVID-
19, those who tested negative and those never tested for 
SARS- CoV-2 (more detailed in online supplemental table 6). 
Individuals who tested negative reported 29%–91% higher 
prevalence of symptoms than those never tested for 
SARS- CoV-2 (see online supplemental table 7), while individ-
uals with a confirmed COVID-19 diagnosis had, compared 
with all others, dramatically increased adjusted risk ratios of 
all symptoms: 3.49 for gastrointestinal symptoms, 3.66 for 
myalgia, 4.16 for fatigue, 4.58 for sore throat, 4.64 for head-
ache, 9.26 for shortness of breath, 19.10 for fever and 32.52 
for impaired sense of taste or smell (see online supplemental 
table 8).
We found that influenza- like symptom burden was posi-
tively associated with symptom levels of depression, anxiety 
and PTSD, regardless of COVID-19 diagnosis (figure 2, online 
supplemental table 9). A stepwise increase across tertiles in 
influenza- like symptom burden was associated with a rise in 
mean levels of depression, anxiety and PTSD among patients 
recovering from COVID-19, individuals who tested negative 
and those never tested for SARS- CoV-2. Patients recovering 
from COVID-19 reporting low to medium influenza- like 
symptom burden (low and mid tertiles) presented with lower 
levels of depression and anxiety compared with those with 
same levels of influenza- like symptom burden but without a 
diagnosis of COVID-19 (figure 2, online supplemental table 
9).
Finally, when influenza- like symptom burden was added to 
the multivariable models (presented in table 2), the direction 
Table 2 The prevalence, crude and multivariable adjusted relative risks and absolute differences in symptoms of depression 
(PHQ-9), anxiety (GAD-7) and PTSD (PC- PTSD-5) surpassing screening thresholds among individuals with and without a 
confirmed diagnosis of COVID-19
Number (%)











Depression 2992 (16.2) 75 (22.1) 1.36 (1.11 to 1.67) 1.48 (1.20 to 1.82) 5.9 8.4
Anxiety 2120 (11.3) 45 (13.1) 1.16 (0.88 to 1.53) 1.24 (0.93 to 1.64) 1.8 2.6
PTSD 2699 (15.6) 59 (19.5) 1.25 (0.99 to 1.57) 1.38 (1.09 to 1.75) 3.9 7.2
*Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, 
bachelor’s degree/diploma certificate, or master’s/PhD degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric 
disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥2), and timing of responding to the baseline questionnaire (24–30 April, 1–7 May, 
8–23 May or 24 May–22 July).
aRR, adjusted relative risk; cRR, crude relative risk; GAD, General Anxiety Disorder; PC- PTSD-5, Primary Care Posttraumatic Stress Disorder Screen for DSM-5; 
PHQ, Patient Health Questionnaire.
6 Saevarsdóttir KS, et al. BMJ Open 2021;11:e049967. doi:10.1136/bmjopen-2021-049967
Open access 
of the aRRs of depression (0.63, 95% CI 0.51 to 0.77) and 
PTSD (0.73, 95% CI 0.57 to 0.93) reversed in patients recov-
ering from COVID-19 compared with others, indicating 
that influenza- like symptoms mediated the risks of mental 
morbidity in this otherwise prepandemic healthy population.
DISCUSSION
The findings of this study suggest that patients recovering 
from COVID-19 may experience elevated risks of depres-
sion and PTSD, particularly if recovering from a severe 
disease. We found that mental morbidities among patients 
recovering from COVID-19 were strongly associated with 
older age, higher educational level, greater influenza- like 
symptom burden, extended time confined to bed and 
hospitalisation due to COVID-19.
To our knowledge, this is the first study addressing 
mental morbidities among patients recovering from 
COVID-19 in a general population setting, including 
outpatients. Our findings are in line with the vast liter-
ature reporting high rates of mental morbidities among 
current or discharged COVID-19 inpatients.9 10 12 13 
Several mechanisms may play a role in the increased risk 
of mental health morbidities among patients recovering 
from a severe COVID-19 illness. These include worries 
and fear of infecting others, shame or stigma associated 
with being infected with COVID-19,37 and uncertainty 
of the prognosis.18 Indeed, the diagnosis of potentially 
life- threatening diseases, for example, cancer, has previ-
ously been associated with a dramatic rise in risks of 
psychiatric disorders38 and suicide.39 In addition, dysreg-
ulated immune response, for example, the documented 
cytokine storm associated with COVID-19,40 may inde-
pendently affect risks of psychiatric disorders in patients 
with COVID-19,19 as has been documented in patients 
with other infections.41 In line with Wang et al,42 we 
found that individuals with a higher educational level are 
more likely than those with a lower educational level to 
suffer from symptoms of depression and anxiety after a 
COVID-19 diagnosis. These findings are intriguing and 
require further investigation as previous studies have also 
provided contradicting results.43
Our mediation analysis suggests that influenza- like 
symptom burden mediated the risk elevations in psychi-
atric morbidities among patients recovering from 
COVID-19. Moreover, influenza- like symptoms among 
individuals without a confirmed COVID-19 diagnosis 
Table 3 Prevalence and adjusted relative risks (95% CI) of mental morbidities among patients recently recovering from 
COVID-19 by disease and symptom severity
n
Depression Anxiety PTSD
%≥10 PHQ-9 aRR* (95% CI) %≥10 GAD-7 aRR* (95% CI) %≥4 PC- PTSD-5 aRR* (95% CI)
Confined to bed due to COVID-19
  Never 136 10.9 Ref. 9.9 Ref. 15.6 Ref.
  1–6 days 131 24.2 2.12 (1.11 to 4.02) 11.3 1.13 (0.55 to 2.32) 18.2 0.94 (0.53 to 1.69)
  7 days or more 105 33.3 3.67 (1.97 to 6.86) 19.4 2.58 (1.29 to 5.15) 26.2 1.65 (0.92 to 2.96)
Hospitalised for COVID-19
  No 341 19.9 Ref. 12.7 Ref. 18.3 Ref.
  Yes 32 48.1 2.72 (1.67 to 4.44) 17.2 1.74 (0.85 to 3.57) 32.0 2.05 (0.97 to 4.32)
COVID-19 symptom severity
  Lowest tertile 115 5.8 Ref. 4.9 Ref. 9.6 Ref.
  Mid tertile 161 18.8 2.70 (1.16 to 6.28) 12.1 2.15 (0.81 to 5.70) 20.1 1.76 (0.88 to 3.55)
  Highest tertile 97 47.1 6.42 (2.77 to 14.87) 23.9 3.91 (1.45 to 10.51) 30.7 2.70 (1.30 to 5.59)
*Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, 
bachelor’s degree/diploma certificate, or master’s/PhD degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric 
disorder (yes or no), number of previously diagnosed somatic diseases (0, 1 or ≥2), and timing of responding to the baseline questionnaire (24–30 April, 1–7 May, 
8–23 May, or 24 May–22 July).
aRR, adjusted relative risk; cRR, crude relative risk; GAD, General Anxiety Disorder; PC- PTSD-5, Primary Care Posttraumatic Stress Disorder Screen for DSM-5; 
PHQ, Patient Health Questionnaire.
Figure 1 The proportion of individuals with and without 
(tested and not tested) a confirmed diagnosis of COVID-19 
with influenza- like symptoms of 1 week or more during 
the last 2 months before responding to the baseline 
questionnaire.
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were also strongly associated with symptoms of mental 
morbidities, suggesting that the association is not limited 
to COVID-19. Indeed, patients with a COVID-19 diagnosis 
reporting low–medium influenza- like symptom burden 
had lower levels of depression and anxiety than individ-
uals without a diagnosis of COVID-19 but with similar 
levels of influenza- like symptoms. While the healthy 
prepandemic profile of the COVID-19 population may be 
an indicator of psychological resilience during recovery 
from COVID-19, it is also possible that the systematic, 
daily surveillance calls to all COVID-19 patients from the 
specialised COVID-19 outpatient clinic at the National 
University Hospital had a positive mental health impact 
on patients.
This population- based study includes more than 20% 
of all patients diagnosed with COVID-19 by RT- PCR 
during the first wave of the epidemic in Iceland. The diag-
nostic rate in Iceland was among the highest worldwide 
during the first wave of the epidemic,44 45 allowing us to 
perform sensitivity analyses limited to individuals who all 
had been screened for SARS- CoV-2. The extensive and 
well- piloted questionnaire allowed us to obtain validated 
symptom assessment of mental morbidities along with 
detailed information on influenza- like symptom burden 
for all individuals during the influenza season in Iceland, 
together with a wide range of potential confounders in the 
association between COVID-19 and mental morbidities.
However, our study is cross- sectional and, therefore, 
less informative on the directionality of the studied asso-
ciations. Indeed, a newly published study using data from 
the UK Biobank suggests that individuals with a history 
of prepandemic psychiatric disorders are more likely 
to be hospitalised and die from COVID-19.46 Thus, it is 
possible that patients who were already experiencing 
psychological symptoms suffered the most severe COVID-
19- related symptomology yielding the observed asso-
ciations. However, we included previous diagnoses of 
psychiatric disorders in all our models which should, to 
some extent, alleviate this concern. Nevertheless, it is 
possible that individuals with severe symptoms of depres-
sion and anxiety were more likely to report high levels of 
influenza- like symptoms during the preceding 2 months 
when responding to the questionnaire, yielding a detri-
mental outcome- dependent misclassification. Indeed, 
the instrument to assess influenza- like symptom burden 
included similar items (eg, fatigue) as are included in the 
PHQ-9 instrument which could, to some extent, explain 
the association between COVID-19 and depression. Yet, 
more objective assessments of illness severity, for example, 
the number of days confined to bed or hospitalised due to 
COVID-19—both of which were strongly associated with 
mental morbidities among patients—might to a lesser 
extent be influenced by the participants’ mental status.
Participants recovering from COVID-19 may differ in 
terms of their mental health status from patients diag-
nosed with COVID-19 who did not participate in our 
study. While we were not able to disentangle the direction 
of such selection, our observed prevalence of depression 
and anxiety among patients recovering from COVID-19 
resembles prevalence rates recently reported in a meta- 
analysis of diverse COVID-19 patient populations else-
where.9 Finally, our study is nested within a small, 
economically and socially secure society with virtually free 
and high- quality healthcare for all, thus, the findings may 
not be generalisable to other settings.
In conclusion, the relatively healthy first- wave COVID-19 
population in Iceland presented with increased risk 
of depression and PTSD in the early weeks of recovery 
Figure 2 Adjusted symptom scores of depression, anxiety and posttraumatic stress disorder (PTSD) by influenza- like 
symptom burden among individuals with a recent COVID-19 diagnosis, those who tested negative and those never tested for 
SARS- CoV-2.
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from their illness, particularly those recovering from a 
severe disease. These findings motivate further follow- up 
studies of mental health among patients recovering from 
COVID-19 and other serious infections and heightened 
clinical surveillance of those recovering from a severe 
illness.
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